Projects

Building a world-class biotech facility with BeiGene

A new state-of-the-art manufacturing facility to support Biotech's growing commercial and clinical demands.

Key information

Client BeiGene

Location Greater China

Project type Real estate

Services Controls and performance, Cost and commercial management, Procurement and supply chain, Programme advisory, Project management

Project timeline 2021 - 2023

Factory building with glass windows on sunny day

Contact

Peter Li

Director

State-of-the-art facility

The company broke ground on a new small molecule manufacturing facility in Suzhou that will have the capability to produce up to 600 million solid oral dosages annually. This supports its expanding pipeline of small molecule medicines and drug candidates as it seeks to find medicines which fight cancer.

Once complete, the new facility was set to significantly enhance in-house manufacturing and research and design capabilities, helping to deliver BeiGene's strategy for innovative anti-cancer medicines.

The first phase of the project included a lab building, warehousing, production building and outdoor landscaping and bicycle storage.

project story

Design management

We worked with BeiGene as an integrated project manager to manage the design, construction, quality, schedule, environment, health and safety, procurement and costs to make sure the project met its objectives.

Construction began in September 2021. The project was expected to achieve mechanical completion in July 2023 and finish commissioning and qualification in January 2024.

Creating opportunities

A key employer in the region, the project was expected to create around 300 new job opportunities for BeiGene. With strong environmental requirements, the building was set to meet Chinese grade two green building standards, aligning with BeiGene’s design to be a sustainable business.

Biotech company BeiGene’s existing 13,000 sqm manufacturing facility in Suzhou, China, produces around 100 million tablets and capsules each year, and houses a biologics clinical development production facility. But the company’s growing commercial and clinical demands meant it needed to expand its site.